More specifically, the efficacy of the injectable GLP‐1 RAs semaglutide 1 mg once weekly and liraglutide 1.8 mg once daily in inducing weight loss (WL) and weight maintenance in people with T2DM has led to clinical trials assessing higher doses of these molecules as treatments for obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.